Clinical Trial Update: Safety Study of Human IgM (MORAb-028) to Treat Metastatic Melanoma [Phase 1]

View source ↗

Summary

Phase 1 safety study of MORAb-028 (a human IgM monoclonal antibody) for metastatic melanoma has been terminated. No results are provided in this update.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• MORAb-028 (human IgM monoclonal antibody)

Snippet

Sponsor: Morphotek | Conditions: Melanoma | Phase 1 | Status: TERMINATED